Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
44 hedge funds and large institutions have $42.6M invested in Regulus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 7 closing their positions.
424% more call options, than puts
Call options by funds: $702K | Put options by funds: $134K
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
72% more capital invested
Capital invested by funds: $24.8M → $42.6M (+$17.8M)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
42% more funds holding
Funds holding: 31 → 44 (+13)
0.86% more ownership
Funds ownership: 2.9% → 3.76% (+0.86%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.2M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.52M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$2.94M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$2.56M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.56M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.17M |
| 3 |
Renaissance Technologies
New York
|
-$606K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$113K |
| 5 |
BlackRock
New York
|
-$70.3K |
RGLS Hedge Fund Activity: Q1 2021 in Review
44 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2021, worth a combined $42.6M — up 72% from $24.8M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RGLS positions and 7 closed out — a net gain of 13 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.2M. The largest seller was BVF Inc, exiting entirely with an estimated $4.56M sold.
- 44 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2021, up from 31 in Q4 2020.
- Funds reported $42.6M of Regulus Therapeutics stock for Q1 2021, up 72% quarter-over-quarter.
- 20 funds opened new Regulus Therapeutics positions in Q1 2021 and 7 closed out, a net change of +13 holders.
- The largest Regulus Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $4.2M added.
- The largest Regulus Therapeutics seller in Q1 2021 was BVF Inc, an estimated $4.56M sold.
Based on aggregated 13F filings for Q1 2021.